Rasna Therapeutics Stock Performance
| RASP Stock | USD 0.0005 0.00 0.00% |
The company holds a Beta of 0.0, which implies not very significant fluctuations relative to the market. the returns on MARKET and Rasna Therapeutics are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Rasna Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Even with inconsistent performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in February 2026. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors. ...more
Rasna |
Rasna Therapeutics Relative Risk vs. Return Landscape
If you would invest 0.40 in Rasna Therapeutics on October 30, 2025 and sell it today you would lose (0.35) from holding Rasna Therapeutics or give up 87.5% of portfolio value over 90 days. Rasna Therapeutics is currently does not generate positive expected returns and assumes 11.1125% risk (volatility on return distribution) over the 90 days horizon. In different words, 99% of pink sheets are less volatile than Rasna, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Rasna Therapeutics Target Price Odds to finish over Current Price
The tendency of Rasna Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.0005 | 90 days | 0.0005 | about 90.17 |
Based on a normal probability distribution, the odds of Rasna Therapeutics to move above the current price in 90 days from now is about 90.17 (This Rasna Therapeutics probability density function shows the probability of Rasna Pink Sheet to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Rasna Therapeutics has the beta coefficient that is very close to zero indicating the returns on DOW JONES INDUSTRIAL and Rasna Therapeutics do not appear to be sensible. Additionally It does not look like Rasna Therapeutics' alpha can have any bearing on the current valuation. Rasna Therapeutics Price Density |
| Price |
Predictive Modules for Rasna Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Rasna Therapeutics. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Rasna Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Rasna Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Rasna Therapeutics is not an exception. The market had few large corrections towards the Rasna Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Rasna Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Rasna Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.00 | |
β | Beta against Dow Jones | 0.00 | |
σ | Overall volatility | 0 | |
Ir | Information ratio | 0.00 |
Rasna Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Rasna Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Rasna Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Rasna Therapeutics generated a negative expected return over the last 90 days | |
| Rasna Therapeutics has high historical volatility and very poor performance | |
| Rasna Therapeutics has some characteristics of a very speculative penny stock | |
| Rasna Therapeutics currently holds 91.97 K in liabilities with Debt to Equity (D/E) ratio of 0.2, which may suggest the company is not taking enough advantage from borrowing. Rasna Therapeutics has a current ratio of 0.04, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Rasna Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Rasna Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Rasna Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Rasna to invest in growth at high rates of return. When we think about Rasna Therapeutics' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (686.59 K) with profit before overhead, payroll, taxes, and interest of 0. | |
| Rasna Therapeutics currently holds about 10.52 K in cash with (312.66 K) of positive cash flow from operations. | |
| Roughly 85.0% of Rasna Therapeutics outstanding shares are owned by corporate insiders |
Rasna Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Rasna Pink Sheet often depends not only on the future outlook of the current and potential Rasna Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Rasna Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 111.4 M | |
| Cash And Short Term Investments | 39.4 K |
Rasna Therapeutics Fundamentals Growth
Rasna Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Rasna Therapeutics, and Rasna Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Rasna Pink Sheet performance.
| Return On Equity | -2.94 | |||
| Return On Asset | -3.7 | |||
| Current Valuation | 1.22 M | |||
| Shares Outstanding | 771.81 M | |||
| Price To Book | 0.31 X | |||
| EBITDA | 254.41 K | |||
| Cash And Equivalents | 10.52 K | |||
| Total Debt | 91.97 K | |||
| Debt To Equity | 0.20 % | |||
| Book Value Per Share | (0.01) X | |||
| Cash Flow From Operations | (312.66 K) | |||
| Total Asset | 85.28 K | |||
About Rasna Therapeutics Performance
Assessing Rasna Therapeutics' fundamental ratios provides investors with valuable insights into Rasna Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Rasna Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Rasna Therapeutics, Inc., a leukemia-focused biotechnology company, engages in developing therapeutics for the treatment of acute myeloid leukemia and other forms of leukemia and lymphoma. Rasna Therapeutics, Inc. was founded in 2013 and is headquartered in New York, New York. Rasna Therapeutics operates under Biotechnology classification in the United States and is traded on OTC Exchange.Things to note about Rasna Therapeutics performance evaluation
Checking the ongoing alerts about Rasna Therapeutics for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Rasna Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Rasna Therapeutics generated a negative expected return over the last 90 days | |
| Rasna Therapeutics has high historical volatility and very poor performance | |
| Rasna Therapeutics has some characteristics of a very speculative penny stock | |
| Rasna Therapeutics currently holds 91.97 K in liabilities with Debt to Equity (D/E) ratio of 0.2, which may suggest the company is not taking enough advantage from borrowing. Rasna Therapeutics has a current ratio of 0.04, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Rasna Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Rasna Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Rasna Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Rasna to invest in growth at high rates of return. When we think about Rasna Therapeutics' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (686.59 K) with profit before overhead, payroll, taxes, and interest of 0. | |
| Rasna Therapeutics currently holds about 10.52 K in cash with (312.66 K) of positive cash flow from operations. | |
| Roughly 85.0% of Rasna Therapeutics outstanding shares are owned by corporate insiders |
- Analyzing Rasna Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Rasna Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Rasna Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Rasna Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Rasna Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Rasna Therapeutics' pink sheet. These opinions can provide insight into Rasna Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Rasna Pink Sheet Analysis
When running Rasna Therapeutics' price analysis, check to measure Rasna Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rasna Therapeutics is operating at the current time. Most of Rasna Therapeutics' value examination focuses on studying past and present price action to predict the probability of Rasna Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rasna Therapeutics' price. Additionally, you may evaluate how the addition of Rasna Therapeutics to your portfolios can decrease your overall portfolio volatility.